The optimization of recombinant antibody production from Chinese hamster ovary (CHO) cells presents a paramount challenge with the biopharmaceutical industry. A variety of strategies are employed enhance antibody titer, comprising process parameter optimization, genetic engineering, and adoption of perfusion processes. Fine-tuning culture conditi